Somaxon Pharmaceuticals (SOMX) says it's entered into a settlement agreement with Actavis...

|About: Somaxon Pharmaceuticals, Inc. (SOMX)|By:, SA News Editor

Somaxon Pharmaceuticals (SOMX) says it's entered into a settlement agreement with Actavis Elizabeth LLC and Actavis to resolve four patent litigation suits involving its Silenor 3 mg and 6 mg tablets. The settlement grants Somaxon an additional seven years protection on its patent, allowing Actavis the right to begin selling a generic version of Silenor on January 1, 2020, or earlier under certain circumstances. Shares +12% AH.